Successful Treatment of Very Early Thrombosis of SAPIEN 3 Valve with Direct Oral Anticoagulant Therapy

J Heart Valve Dis. 2016 Mar;25(2):211-213.

Abstract

Thrombosis of transcatheter aortic valve implantation (TAVI) is an uncommon complication that commonly occurs weeks to months following the procedure. Herein are described the details of a patient who presented with a recurrence of symptoms days after intervention with a bioprosthesis thrombosis that was successfully treated with direct oral anticoagulant (DOAC) therapy and resulted in hemodynamic improvement and resolution of symptoms. Whilst a previous trial of DOAC therapy with mechanical valves was stopped due to elevated events in comparison to warfarin, a TAVI valve may be different, and the rapid onset of action and reduced bleeding risk may be beneficial in this patient group.

Publication types

  • Case Reports
  • Video-Audio Media

MeSH terms

  • Administration, Oral
  • Aged, 80 and over
  • Aortic Valve / physiopathology
  • Aortic Valve / surgery*
  • Aortic Valve Stenosis / physiopathology
  • Aortic Valve Stenosis / surgery*
  • Bioprosthesis*
  • Blood Coagulation / drug effects*
  • Echocardiography, Three-Dimensional
  • Echocardiography, Transesophageal
  • Factor Xa Inhibitors / administration & dosage*
  • Heart Valve Prosthesis*
  • Hemodynamics
  • Humans
  • Male
  • Prosthesis Design
  • Rivaroxaban / administration & dosage*
  • Thrombosis / blood
  • Thrombosis / drug therapy*
  • Thrombosis / etiology
  • Time Factors
  • Tomography, X-Ray Computed
  • Transcatheter Aortic Valve Replacement / adverse effects
  • Transcatheter Aortic Valve Replacement / instrumentation*
  • Treatment Outcome

Substances

  • Factor Xa Inhibitors
  • Rivaroxaban